Provided by Tiger Fintech (Singapore) Pte. Ltd.

Q32 Bio Inc.

2.00
+0.16008.70%
Post-market: 2.000.00000.00%16:05 EDT
Volume:121.08K
Turnover:237.01K
Market Cap:24.40M
PE:-0.30
High:2.01
Open:1.85
Low:1.85
Close:1.84
Loading ...

Company Profile

Company Name:
Q32 Bio Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
43
Office Location:
830 Winter Street,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Directors

Name
Position
Arthur O. Tzianabos
President, Chief Executive Officer and Director
Kush M. Parmar
Chairman of the Board, Independent Director
Alise S. Reicin
Independent Director
Mary Thistle
Independent Director
Matthew R. Patterson
Independent Director
Richard James Gregory
Independent Director
Steven Gillis
Independent Director

Shareholders

Name
Position
Arthur O. Tzianabos
President, Chief Executive Officer and Director
Bradford Smith
Chief Financial Officer, Treasurer and Secretary
Albert Seymour
Chief Scientific Officer
Gabriel M. Cohn
Chief Medical Officer
Tim Kelly
Chief Technical Operations Officer